Australian biotech market watch 19/06/09
Friday, 19 June, 2009
The All Ordinaries has had a turbulent week, shedding some of the gains made in the previous seven days, although Friday was mainly level, with the All Ords sitting at 3190 at 4:15pm on Friday.
Contrasting the flagging performance of the All Ordinaries, the health indices are up on Friday nearly 1.5% from last week.
CSL (ASX:CSL), the smallest of the six big vaccine makers worldwide, is pipped to have a swine flu vaccine first, and this optimism has resulted in some lifts in CSL's share price over the last few weeks. Today it's up 42c to $31.55.
Cochlear (ASX:COH) has gone through a few wobbles this week, finishing on $56.84, only a few cents off its start on Monday of $56.92.
Amongst the losers is Ansell (ASX:ANN), down 1.6% to $8.80, and Blackmores (ASX:BKL), dropping 4.7% after riding high on the threats from swine flu, which appear to be subsiding with the federal government reducing the alert level on Wednesday.
Novogen (ASX:NRT) has also slipped another 13% today to 62c, down a full 40% from its peak on May 19 of $1.02.
Ramsay Health Care has seen a slight slide over the last couple of days down to $11.07.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
